Fig. 4

Healthcare resource utilization and costs in matched spironolactone users and non-users. (A) Proportion of patients hospitalized in the post-inclusion period stratified by CKD stage at inclusion. (B) Total median post-inclusion healthcare costs stratified by CKD stage at inclusion. CKD, chronic kidney disease; CV, cardiovascular; DKD, diabetic kidney disease; ESRD, end-stage renal disease; RRT, renal replacement therapy